Flag of the European Union EU Clinical Trials Register Help

Clinical trials for McDonald criteria

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    274 result(s) found for: McDonald criteria. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-003903-35 Sponsor Protocol Number: : NUTH-2005-03384 Start Date*: 2006-01-19
    Sponsor Name:Newcastle-upon-Tyne Hospitals NHS Trust
    Full Title: : The Role of Keppra in the Treatment of Tremor in Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003706-33 Sponsor Protocol Number: 28821 Start Date*: 2009-03-24
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of oral cladribine in subjects with a first clinical event at high risk of converting to MS
    Medical condition: Subjects with a first clinical demyelinating event (Clinically Isolated Syndrome (CIS)) at high risk of converting to Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) FI (Prematurely Ended) EE (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NO (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed) FR (Completed) SE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004128-41 Sponsor Protocol Number: WN42086 Start Date*: 2021-08-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTI...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013884-21 Sponsor Protocol Number: GLPG0303-CL-204 Start Date*: 2009-11-18
    Sponsor Name:Enceladus Pharmaceuticals BV
    Full Title: A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medr...
    Medical condition: Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005989-37 Sponsor Protocol Number: 308841 Start Date*: 2006-03-29
    Sponsor Name:Schering Oy
    Full Title: CogniMS: observational study to assess cognition in patients with early Multiple Sclerosis
    Medical condition: Observational Study to assess cognition in patients with early Multiple Sclerosis. Relapsing-Remitting MS-patients diagnosed within 2 years and who have started the Betaferon treatment (interferon-...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019029-32 Sponsor Protocol Number: CFTY720D2316 Start Date*: 2010-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 4-month, open-label, multi-center study to explore tolerability and safety and health outcomes of FTY720 in patients with relapsing forms of multiple sclerosis.
    Medical condition: Relapsing multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) IT (Completed) GB (Completed) ES (Completed) PT (Completed) SK (Completed) IE (Completed) SE (Completed) FI (Completed) NL (Completed) CZ (Completed) AT (Completed) DK (Completed) GR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016140-39 Sponsor Protocol Number: IDI-GAD-2009-01 Start Date*: 2010-01-19
    Sponsor Name:Institut Diagnostic per la Imatge
    Full Title: MRI in Clinically Isolated Syndromes and relapsing multiple sclerosis after single dose (0.1 mmol/kg) and cumulative dose (0.1 + 0.1 mmol/kg) of GADOVIST at 3.0T Estudio de resonancia magnética 3...
    Medical condition: Realce de contraste en resonancia magnética en pacientes con Síndrome Clínico Aislado o recaída de Esclerosis Múltiple con resonancia magnética anormal anterior después de la administración de dosi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014857-34 Sponsor Protocol Number: FAU-001 Start Date*: 2010-02-01
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T
    Medical condition: Patients with clinically definite MS or a clinically isolated episode of CNS involvement and disease dissemination in space, according to the McDonald’s criteria
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028245 Multiple sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006151-10 Sponsor Protocol Number: FAME1.0 Start Date*: 2012-02-15
    Sponsor Name:Sønderjylland Hospital, department of neurology
    Full Title: FAME - Fampyra outcome measures study: a study of responsiveness of different outcome measures to Fampyra treatment.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003799-13 Sponsor Protocol Number: 25632 Start Date*: 2005-02-03
    Sponsor Name:Serono International SA
    Full Title: A multicentre, single arm, open-label, phase IIIb study to evaluate the safety and antigenicity of Rebif® (IFN-beta-1a) in subjects with relapsing forms of multiple sclerosis.
    Medical condition: Relapsing form of MS ; diagnosis of MS is in accordance with the McDonald criteria
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) IE (Completed) DK (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-004130-14 Sponsor Protocol Number: IMA 04001 Start Date*: 2005-02-17
    Sponsor Name:Biogen Idec GmbH
    Full Title: A multicenter, randomized, rater-blind study to compare the efficacy and safety of natalizumab (300 mg IV every four weeks) with Interferon beta-1a (44 mcg SC three times a week) in subjects with r...
    Medical condition: Male and female subjects with relapsing multiple sclerosis previously treated with interferon beta-1a (22 mcg or 44 mcg, SC three times a week).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003930-16 Sponsor Protocol Number: SIMCOMBIN Start Date*: 2006-01-19
    Sponsor Name:Biogen Idec A/S
    Full Title: A Multi-centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Study Investigating Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Mu...
    Medical condition: Patients with definite relapsing-remitting multiple sclerosis who have never received treatment with interferons or glatiramer acetate, who meet all the criteria for inclusion and none of the exclu...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028425 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002982-38 Sponsor Protocol Number: 27025 Start Date*: 2006-11-29
    Sponsor Name:Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
    Full Title: A phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial of Rebif New Formulation (44 mcg tiw and 44 mcg ow) in subjects at high risk of converting to Multiple Sclerosis
    Medical condition: Subjects at high risk of converting to Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.0 10028245 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) AT (Completed) LT (Prematurely Ended) SK (Completed) DE (Completed) FI (Completed) FR (Completed) EE (Completed) DK (Completed) IT (Completed) GR (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-004158-40 Sponsor Protocol Number: P170702J Start Date*: 2018-09-11
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A Prospective study evaluating the effect of ocrelizumab on brain innate immune Microglial cells Activation in Multiple Sclerosis using PET-MRI with 18F-DPA714
    Medical condition: Patients with Relapsing MS or primary progressive MS
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007459-28 Sponsor Protocol Number: H9B-MC-BCDJ(b) Start Date*: 2009-10-08
    Sponsor Name:Eli Lilly and Company
    Full Title: Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FI (Completed) HU (Completed) CZ (Completed) FR (Completed) DK (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005213-22 Sponsor Protocol Number: SUPREMES-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: SUPREMES - Sunphenon in progressive forms of multiple sclerosis
    Medical condition: primary and secondary progressive forms of multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004255-38 Sponsor Protocol Number: cnp-MS-0601/MC-2006-01 Start Date*: 2007-01-05
    Sponsor Name:Bionorica research GmbH
    Full Title: Multi-centre, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of the pain relieving effect of Dronabinol in patients with multiple sclerosis associated wit...
    Medical condition: Patients with multiple sclerosis associated with central neuropathic pain
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DK (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005679-13 Sponsor Protocol Number: NALTREX005 Start Date*: 2006-06-28
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis.
    Medical condition: multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10053395 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000663-99 Sponsor Protocol Number: C-1900 Start Date*: 2004-09-10
    Sponsor Name:Biogen Idec Inc. [...]
    1. Biogen Idec Inc.
    2. Biogen Idec Ltd
    Full Title: Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis.
    Medical condition: MS is a chronic disease of the CNS. It's a disease of young adults, primarily women, with disease onset typically occuring between the ages of 20 and 40. Although etiology is uncertain, evidence p...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-001176-31 Sponsor Protocol Number: 19215 Start Date*: 2017-09-22
    Sponsor Name:Bayer AG,
    Full Title: BENEFIT 15 long-term follow-up study of the BENEFIT and BENEFIT follow-up studies
    Medical condition: Clinically-isolated syndrome (CIS) and multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10071068 Clinically isolated syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) SE (Completed) GB (Completed) AT (Completed) CZ (Completed) FI (Completed) DK (Completed) BE (Completed) FR (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 15 13:52:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA